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TNF was originally characterized as an antitumor agent and a factor cytotoxic for many malignant cells. It is now clear that it plays an important 
role in the defense against viral, bacterial and parasitic infections, - and in (auto-)immune responses. Natural induction of TWF is protective, but 
its overproduction may he detrimental and even lethal to the host. The steucture of TNF and its interaction with the two types of cellular receptor 
are becoming better understood. TNF elicits a variety of events in different cell types. It subverts the electron transport system or the mitochondria 
into production of oxygen radicals, which can kill the (malignant) cells when these do not contain or produce protective enzymes. Furthermore, 
TNF induces a set of genes and at least part of this transcriptional activation is mediated by NFKB. The prospects of TNF as an antitumor drug 
can be improved on the one hand by agents such as LI+, which synergizes, and on the other hand by inhibitors of the systemic toxicity which 
do not interfere with the antitumor efficacy. Also, in tumor-bearing animals which have been rendered tolerant by administration of small doses 
of TNF, an effective and complete elimination of the tumors can be obtained by the combined action of TNF plus interferon. 
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1. INTRODUCTION 
Already at the end of the 18th century, physicians 
noted that, occasionally, cancer patients who went 
through a severe infection, experienced a shrinkage and 
even an elimination of their tumor. Observations led to 
experimentations, and around the turn of the century, 
William B. Coley, a New York physician, used prepara- 
tions derived from Gram-negative and Gram-positive 
bacteria in the treatment of a variety of cancer patients. 
Although his descriptions have to be seen in the context 
of that period, his extensive series of well-documented 
cases of successful cancer therapy is most impressive, 
even to this day [l]. This clinical testing led to well- 
controlled, fundamental research with animal model 
systems. In 1975, Lloyd Old and co-workers [2] could 
demonstrate unambiguously that treatment of mice or 
rabbits with ‘bacille Calmette-Guerin’ (BCG) for lo-14 
days (stimulation of the reticuloendothelial system), 
followed by injection of lipopolysaccharide (LPS), led 
to the release into the circulation of a protein, which 
they called Tumor Necrosis Factor or TNF. The 
biological activity of this factor could be determined, 
on the one hand, by an in vivo antitumor test; treatment 
of mice carrying a transplantable, methylcholanthrene- 
induced sarcoma with the TNF-containing serum led to 
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a rapid hemorrhagic necrosis and regression. On the 
other hand, the factor could also be shown to have a 
selective cytotoxic effect on a number of malignant cells 
in tissue culture. Remarkably, the selective killing of 
transformed cells was often much more pronounced 
when the treatment with TNF was combined with in- 
terferon (IFN) [3]. There was some evidence that the 
cells responsible for synthesis of TNF in vivo were 
macrophages, which, in the activated state, become 
highly responsive to LPS stimulation [4,S]. Indeed, ap- 
propriate stimulation of activated macrophages or 
monocytic cell lines leads to synthesis and release of 
TNF into the culture medium. A key observation was 
also that, unlike for example IPN activity which 
depends on cellular protein synthesis, TNF action is not 
abolished by co-treatment with transcription or transla- 
tion inhibitors [6]; quite on the contrary, most cells 
become highly sensitive to TNF in the presence of ac- 
tinomycin D or cycloheximide. This indicates that 
cytotoxicity is a nucleus-independent process 
originating in the cytoplasm. It was later shown that not 
only macrophages are able to synthesize TNF, but also, 
after appropriate induction, NK-cells, some T- 
lymphocyte subpopulations (such as CD4+ THl-cells), 
and even some tumor cell lines [7]. 
On the basis of amino acid sequence data derived 
from purified human or rabbit TNF, Pennica et al. [8] 
as well as a number of other groups cloned the human 
TNF (hTNF) cDNA gene (reviewed in [9]). Subsequent- 
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ly, the TNF cQNA genes for pig, cow, rabbit, cat, rat 
and mouse have been reported [9, IO]. Both the human 
and the murine TNF cDNA gene could be expressed at 
very high efficiency in Escherichia co/i. Unlike many 
other heterologous proteins, the recombinant TNF re- 
mained soluble in the bacterial cells and therefore could 
be purified from extracts without denaturation- 
refolding steps. Hence, highly purified hTNF and 
mTNF became available for physico-chemical, 
biological, biochemical and preclinical research, as well 
as for clinical application. The human genomic TNF 
gene is interrupted by three introns. Quite remarkably, 
it is located on the short arm of chromosome 6, about 
200 kbp centromeric of HLA-B in the major histocom- 
patibility complex (MHC) region [I 11. 
The discovery of lymphotoxin (LT), now often refer- 
red to as TNF-6, in fact predates that of TNF [la]. 
Unlike TNF, LT is exclusively made by T-lymphocytes p 
both CD4+ and CDS+ cells, following appropriate 
stimulation in the context of class I1 and class I restric- 
tion, respectively. The gene for LT is closely linked 
(about 1200 bp distance) to the TNF gene within the 
MHC region. Also the LT cDNA gene can be efficiently 
expressed in E. coli [ 131. 
114.171 and the three-dimensional structure was solved _ - 
at 2.6 -A resolution [l&19]. The shape of the molecule 
resembles a triangular cone in which each of the three 
subunits has a typical jelly roll-,& structure. Each 
subunit consists of two P-pleated sheets, five anti- 
parallel P-strands in each. The three subunits are ar- 
ranged edge to face. The outside p-sheet is rich in 
hydrophilic residues, while the inner sheet is hydro- 
phobic and contains the C-terminal segment, which is 
located close to the central axis of the trimer. Quite 
remarkably, the 3D-structure is clearly reminiscent of 
the arrangement of many viral capsids around three- 
fold symmetry axes, such as those found in picor- 
naviruses, in the hemagglutinin of influenza virus and 
in a number of eicosahedral plant viruses. In fact, the 
highest structural homology is with the triangular ar- 
rangement of the Satellite Tobacco Necrosis Virus 
(STNV) capsid protein. Up to 7 1% of the TNF residues 
are structurally equivalent to residues in STNV. It so 
happened that we also had elucidated the primary se- 
quence of STNV capsid protein [20]; not unexpectedly, 
there is no discernible homology in primary structure. 
Obviously, the discovery of a similar conformational 
motif, on the one hand, in TNF and, on the other hand, 
in viral capsids, raises intriguing questions regarding 
convergent or divergent evolution. 
The next question then is where on the TNF molecule 
is (are) the active site(s)? Many changes have been made 
by chemical methods and especially by genetic engi- 
neering approaches [9]. Especially revealing have been 
studies involving screening of randomIy obtained 
mutants selecting those where loss or alteration of func- 
tion was not due to a gross distortion of conformation. 
These mutations cluster in the lower half of the 
triangular pyramid, in the groove between two subunits 
[21,22]. This active site corresponds to the receptor- 
binding domain, and of course also follows the three- 
fold symmetry. 
Since the cloning and expression of the TNF and LT 
genes, proteins, probes, antibodies, assays and other 
related reagents have become widely available. This has 
transformed this previously esoteric field into one of 
the most rapidly expanding areas of biomedIda1 
research. Still more recent analytical (and perhaps 
clinical) tools relate to the membrane-bound and solu- 
ble form of two types of TNF receptor (see below). 
2. THE TNF MOLECULE 
The hTNF cDNA gene codes for a mature polypep- 
tide of 157 amino acids (156 for mTNF), preceded by a 
76 amino acid long presequence [141. The latter is much 
longer than a classical signal sequence and furthermore 
is almost as strongly conserved between different mam- 
malian species as the mature sequence, which suggests a 
specific, essential function (91. Indeed, TNF can also 
exist in an unprocessed, membrane-bound form (26 
kDa protein) [lS]. In this respect, as in many others, 
TNF is analogous to interleukin (IL)-1 (see below). 
The native structure of TNF is a trimer with a total 
molecular mass of 52 kDa. The trimeric structure was 
shown both chemically by cross-linking experiments, as 
well as physico-chemically by analytical ultracen- 
trifugation and by X-ray solution scattering [ 14,16,17]. 
Lower molecular weight estimates obtained by gel 
filtration were presumably due to protein/matrix in- 
teraction. Each of the three subunits contains a 
disulfide bridge which is not essential for biological ac- 
tivity [9]. 
Well-diffracting crystals of TNF have been obtained 
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The hLT precursor starts with a classical 34-amino 
acid long signal sequence followed by the mature pro- 
tein, which contains 171 residues [23]. In agreement 
with this, there is no evidence that LT can also exist in 
a membrane-bound form. There is a natural minor 
form of the hLT protein which lacks the first 23 amino 
acids. hLT does not contain cysteine residues. Unlike 
hTNF, hLT is a glycoprotein (N-glycosylation of posi- 
tion 62), but it may be noted that also mTNF is a 
glycoprotein. The amino acid sequence of mature hLT 
is about 30% identical with that of hTNF and about 
50% homologous. Mainly four regions of sequence 
identity/homology can be recognized and these corre- 
spond to the scaffold domains, centrally located in the 
trimeric structure [24]. This strongly suggests that the 
overall conformation of hLT is very similar to that of 
hTNF. hLT is relatively more resistant to proteases as 
compared to hTNF, but more sensitive to detergents, 
organic solvents and acidic conditions [25]. 
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3. TNF RECEPTORS 
TNF receptors are present on nearly all cell types with 
a few exceptions, such as erythrocytes and unstimulated 
T-lymphocytes. The number of receptors vary from 
about 200 up to 10000, and the binding constant is 
around 2 X lo-” M [la]. Although the presence of the 
TNF receptor is a prerequisite for a biological effect, 
there is no correlation between the number of receptors 
and the magnitude of the response, or even the direction 
of response. 
More recently, it became clear that there are in fact 
two types of TNF receptor, which can be differentiated 
by their size (ligand blotting after denaturing, but non- 
reducing gel electrophoresis), or by monoclonal an- 
tibody recognition [Z-27]. Several groups were able to 
clone the two types of TNF receptor (TN&R) cDNAs 
[%8-301. This was possible using probes based on partial 
amino acid sequence information determined either on 
purified soluble receptor, derived from urine or serum, 
or purified receptor itself. The first TNF receptor has a 
molecular weight of about 55 kDa, and can be referred 
to as TNF-R55 or TNF-RI; the second TNF receptor 
has a molecular weight of about 75 kDa, and can be 
referred to as TNF-R75 or TNF-RII. TNF-R55 seems to 
be ubiquitous and occurs, amongst others, on epithelial 
cells and on fibroblasts. TNF-R75 seems more 
restricted to cells of hematopoietic origin and is, for ex- 
ample, strongly expressed upon induction of T-cells. 
Both TNF-R55 and TNF-R75 bind TNF as well as LT, 
although the latter with lower avidity. The binding con- 
stant for hTNF of TNF-R55 is about & = 0.5 nM, and 
that of TNF-R75 about & ==O.l nM. The extracellular 
domain of TNF-R55 is 182 amino acids long, and that 
of TNF-R75 235 residues. Both are M-glycosylated, but 
only the latter is 0-glycosylated. Both sequences are 
related to each other, and each contains four sequence 
motifs, about 40 residues in length, each containing 6 
(some 4) cysteine residues. This extracellular domain is 
significantly homologous to the extracellular part of 
nerve growth factor receptor (NGF-R) as well as to the 
CDw40 and OX40 antigens, and to an open reading 
frame of Shope fibroma virus. The cytoplasmic domain 
of TNF-R55 is 220 amino acids in length, and that of 
Tr\iF-R95 174 residues. Remarkably, there is no 
homology in this region, and neither domain provides 
any hints as to its function (absence of GTP-binding 
sites, protein kinase sites, etc.). 
Soluble TNF-binding proteins have been characteriz- 
ed both in the serum of cancer patients as well as in 
urine. There are two types, antigenically distinguishable 
and corresponding to the shedded extracellular domains 
of the two species of TNF receptor [31]. Remarkably, 
although binding of ‘251-TNF to both types of TNF 
receptor can be competed out by hLT, the binding of 
[“‘I]TNF to the soluble binding proteins is not 
displaceable by excess hLT [28,29,31,32]. This is cer- 
tainly true for the soluble TNF-R55, but less so for the 
soluble TNF-R75 [31]. The study of the two types of 
soluble TNF receptors in the presence or absence of the 
ligands (TNF and/or LT) in the circulation and in 
various other biological fluids, in function of disease 
state and in function of various treatments, is a vast 
virgin territory, which needs to be thoroughly explored 
in the coming years. The presence of soluble TNF-R in 
the serum may compete and inhibit TNF action on cells, 
but on the other hand, by binding the TNF in a 
dissociable form, it may dramatically affect the phar- 
macokinetics and the stability of TNF [33]. 
It has long been known that the species specificity of 
TNF is complex, as some activities are species-indepen- 
dent, while others are specific (to be discussed in section 
6). With the availability of the cloned receptors it could 
be shown that in the mouse the TNF-855 binds both 
mTNF and hTNF, but, remarkably, the TNF-R75 only 
binds mTNF ([34]; our own unpublished results). This 
discrimination by the two types of TNF-R is not true for 
the human homologues. 
The time course of events after TNF binds to its 
receptor can be followed by electron microscopy using 
gold particle-labeled TNF [35]. The TNF/TNF-R com- 
plexes are internalized via clathrin-coated pits, en- 
dosomes, multivesicle bodies and finally end up in the 
secondary lysosomes, where they are degraded. Unlike 
the mechanism of action of a number of hormones and 
other cytokines, TNF needs to be continuously present 
for many hours in order to fully exert its effect on the 
cell. The two types of TNF receptor can be distinguish- 
ed on the surface of human cells by means of specific 
monoclonal antibodies [27]. Monoclonal antibodies 
directed against the TNF-855 can mimic a number of 
TNF effects, both nucleus-dependent and nucleus- 
independent, for example on fibroblasts and on en- 
dothelial cells [36]. This allows one to conclude first of 
all that these cellular TNF effects are mediated by the 
TNF-R55 receptor (discussed in section 8); Another im- 
portant conclusion is that triggering of the TNF recep- 
tor by its ligand occurs by clustering. This is supported 
by the fact that a multivalent IgM monoclonal antibody 
was considerably more effective than the divalent IgG. 
As mentioned above, a TNF molecule has three poten- 
tial interaction sites with its receptor (the clefts between 
the three subunits) [22]. In this way, the TNF receptors 
can be cross-linked. It remains to be investigated 
whether binding of the bona fide ligand, TNF, has addi- 
tional effects than simple clustering, as mimicked by 
monoclonal antibodies. Also, the mechanism of trigger- 
ing the TNF-R75 by TNF remains at present unknown. 
4. TNF ACTION ON CELLS IN CULTURE 
The original interest in TNF mainly arose from its 
selective toxic action on malignant cells. The classical 
cell line for testing TNF cytotoxicity is the murine 
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fibrosarcoma line L929, although nowadays other cell HLA structures, etc. [reviewed in 49,501 can be men- 
tioned. Examples of induced proteins which are 
secreted, are IL6, GM-CSF, M-CSF and plasminogen 
activator inhibitor [SOJIJ. 
lines are available which are even more sensitive, such 
as WEHI clone 13 [37]. The cytotoxic action of TNF 
is nucleus-independent and in fact the sensitivity of the 
cytotoxic assay can be increased 50- to lOO-fold in the 
presence of actinomycin D or cycloheximide [6]. It was 
originally reported by Williamson et al. [3] that the 
cytotoxic action of TNF on many cell types is con- 
siderably enhanced by IFN. This was clearly confirmed 
when the recombinant protein became available 
[ 14,38,39]. This difference between many malignant 
cells as compared to normal cells in response to the 
combined action of TNF and IFN is one of the most 
dramatic manifestations of the aberrant metaboIism in 
the former. Usually the synergism can be obtained both 
with type I-IFN (IFN-a or IFN-,&), as well as with type 
II-IFN (IFN-y), but sometimes type I-IFNs are more ef- 
fective. Interestingly, the selective toxic effect of 
natural IFN-y preparations on a number of malignant 
ceII Iines couId not be reproduced with the cloned, 
recombinant IFN-7, and was presumably due to con- 
tamination of the former preparations with LT. Unlike 
IFNs, which have an anti-proliferative effect on a 
number of cell lines due to a cytostatic or anti-mitogenic 
action, TNF actually causes lysis of the target ceils. But 
this is not the only way that TNF can kill. In some cell 
types TNF action leads to apoptosis [40-421. 
Teleologically, cell death in vivo by apoptosis means 
that the shrunken body can be removed by engulfment, 
rather than a lysis process which releases all kinds of 
molecular domains which should not be seen by the im- 
mune system. 
On many types of cells, even in the absence of protein 
synthesis, TNF causes release of arachidonic acid 
[14,43,44], and, when the proper enzymes are present, 
this leads to secretion of prostaglandins, especially 
PGE2, and some other eicosanoids [45]. Treatment of, 
for example, endothelial cells with TNF also induces 
synthesis of platelet-activating factor (PAF); in this 
case, induction of new enzymes may be involved [46]. 
TNF added to neutrophils leads, within minutes, to a 
respiratory burst and degranulation, releasing elastase, 
lysozyme and other enzymes [47,48]. 
The addition of TNF to many cell types induces a 
various set of genes by transcriptional activation., This 
has been studied in more detail in a number of cell 
types, such as fibroblasts and especially endothelial 
cells, as these are the main targets when TNF appears in 
the circulation. Gene products induced by TNF can be 
found in the nucleus, such as c-fos and c-jun, in 
organelIes such as Mn-superoxide dismutase (MnSOD) 
in the mitochondria, in the cytoplasm, on the cell mem- 
brane, or secreted in the medium. Among the new an- 
tigens appearing on the endothelial membrane, the pro- 
coagulant factor, the leukocyte adhesion molecule E- 
LAM-l, membrane;bound ILl, an enhancement of the 
lymphocyte adhesion molecule I-CAM-l and of class I- 
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On a number of cell types, especially primary 
fibroblasts, TNF in fact exerts a mitogenic activity 
[39,42,53]. Presumably, this is due to induction of pro- 
teins promoting cell cycling. On the other hand, the fact 
that blocking RNA or protein synthesis so strongly 
enhances the cytotoxicity of TNF, is often explained by 
assuming that TNF itself induces the synthesis of pro- 
tective proteins [54], which either interfere with the 
generation of toxic products or else help to detoxify 
these. In fact the two phenomena may be linked; TNF 
stimulation of a cell may lead to synthesis of effecters, 
which are responsible for the mitogenic response, but 
which, when the latter is not allowed to proceed, 
become toxic/lethal. The activity of TNF on a number 
of other cell types, such as macrophages, osteoblasts 
(involved in bone resorption), cbondrocytes, T- 
lymphocytes and B-lymphocytes, has been reviewed by 
Balkwill [55]. 
We have seen above that hLT binds both to the clon- 
ed TNF-R55 and to the TNF-R75, albeit with a lower 
binding affinity. Hence one would expect that in- 
dependently of whether cells exhibit one or other or 
both of these receptors, they would respond similarly to 
either cytokine, except that higher concentrations of 
hLT would be needed. However, this is clearly not so; 
there are a number of biological systems where TNF is 
effective, while LT is not (reviewed in [56,57]). For ex- 
ample, TNF induces production of GM-CSF, M-CSF 
and IL1 in endothelial cells, while LT has almost no ac- 
tivity; on the other hand, LT has a proliferative effect 
on some B-lymphoblastoid cells, which is not shared 
with TNF. Among tumor cell lines, the relative sen- 
sitivity towards TNF as compared to LT differs very 
significantly [%I. As these results cannot be correlated 
with the relative involvement of one or other of the two 
TNF receptors, it seems much more likely that the TNF 
receptor molecules are associated with accessory pro- 
teins, and that interaction with TNF generates several 
signals, not all of which can be exerted by LT. Alter- 
natively, it can still not be excluded that there is a third 
type of receptor. 
5. TNF: INVOLVEMENT IN INFLAMMATION, 
AUTOIMMUNITY, INFECTIOUS DISEASES 
AND SEPTIC SHOCK 
Cerami and colleagues [59,60] have studied for many 
years the severe wasting, called cachexia, which often 
accompanies chronic parasitic, bacterial or viral infec- 
tion, and is also all too often a major symptom of 
cancer patients. Infected cattle may lose up to 50% of 
their weight. Cachexia can be induced in rabbits by in- 
fection with Trypanosoma brucei. The animals have a 
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high triglyceride level in circulation, presumably due to 
interference of clearance by a depressed lipoprotein 
lipase activity. A factor was identified in the serum, 
which not only mediated lipoprotein ljpase inhibition in 
vivo, but also suppressed this enzyme in 31’3-El 
adipocytes in tissue culture. This factor, called cachec- 
tin, was purified, partially sequenced and turned out to 
be identical to TNF. This then led to a series of 
pathophysiological studies [60-621. 
I). It should be noted in this resuect that the action of 
Many of the effects observed in animals with a 
chronic parasitic burden, could also be mimicked by ad- 
ministration of LPS. Indeed, we have mentioned above 
that LPS is a major inducer of TNF, both in vitro and 
in vivo. Infection with Gram-negative bacteria or high 
doses of LPS can lead to septic shock. That TNF plays 
a pivotal role in septic shock was demonstrated by 
pretreating mice or baboons with antibodies against 
TNF and in this way they became protected against a 
lethal challenge with LPS [61,62]. Another indication 
for a key role of TNF in septic shock was reported by 
Waage et al. [63]. In a retrospective study they found 
that septic sh.ock with fatal outcome was significantly 
correlated with high levels of TNF in the serum. 
Malaria is undoubtedly the most important parasitic 
disease of man. About 0.5-l% of the patients develop 
cerebral malaria, which is often fatal, especially in 
children. It was found that plasmodium infection 
results in an increase in circulating TNF levels, and 
Grau et al. [64,65] reported that treatment of infected 
mice with anti-TNF antibodies could protect them 
against the cerebral complications. 
But not only parasitic and bacterial infections can 
become more pathogenic or fatal due to TNF in circula- 
tion, this may also be true for some viral infections. For 
example, CD4+ T-cells latently infected by I-IIV can be 
stimulated to active viral replication by TNF. In 
children with AIDS, elevated serum levels of TNF cor- 
relate with progressive encephalopathy [66]. 
It would of course be difficult to comprehend how a 
molecule could have been devised in the course of 
evolution with such detrimental properties. In fact, 
quite on the contrary, there are numerous indications 
that the major role of TNF is as an important mediator 
of protection against parasitic, bacterial and viral infec- 
tions (reviewed in [63]). The deleterious effects men- 
tioned above should be seen as aberrant situations, such 
as overreaction of the host or deficiency of a natural, 
autoregulatory network. There are multiple ways in 
which TNF contributes to the combat against infection, 
such as activation of neutrophils and platelets, enhance- 
ment of the killing activity of macrophages and NK- 
cells, activation of the immune system, etc. 
Remarkably, many cell types infected by viruses or even 
bacteria become highly susceptible to the cytotoxic ef- 
fect of TNF. 
TNF also plays a role in pathophysiological events 
occurring in a number of autoimmune diseases (Table 
TNF may be to some extent lodiy restricted and due to 
the membrane-bound form, similar to the situation 
with ILl. TNF interacts in a complex way with the im- 
mune compartment and with the vascular system 
leading to release of cytokines, expression of new sur- 
face determinants, and production of other mediators, 
such as PAF and eicosanoids [7]. In other cases, such as 
rheumatoid arthritis, TNF is often present at the site of 
inflammation, but a causal link has still to be proven 
[55]. In organ transplantation, ischemia/reperfusion in- 
jury is difficult to avoid, but the deleterious effects can 
clearly be alleviated by pretreament with antibodies 
against TNF [683. Furthermore, both organ rejection 
and graft-versus-host disease can be prevented or 
diminished by anti-TNF therapy, or by treatments 
which prevent the synthesis of endogenous TNF. It may 
also be noted that the immunosuppressive treatment 
with the mono&ma1 antibody 0KT3, directed against 
activated T-cells, has a toxic side effect which is due to 
induction of TNF, presumably triggered by interaction 
with the Fc-receptors on effector cells [69,70]. This tox- 
icity can be avoided either by using F(ab’)2 fragments 
or by administration of drugs which prevent en- 
dogenous TNF synthesis, such as steroids or pentoxi- 
fylline. 
From the above, it might be concluded that TNF, 
either endogenously produced or injected as a drug, is 
a dangerous, sometimes even lethal molecule. But the 
truth is much more complex and subtle. For example, 
Kiener et al. [71] described a non-toxic derivative of 
LPS, viz. monophosphoryl lipid A, which upon injec- 
tion, nevertheless induced the same level of TNF in cir- 
Table I 
Diseases in which TNF is/may be involved 
Infection Auto-immunity 
Septicemia, septic shock 
Toxic shock syndrome 
BCG infection/TBC 
Lepra 
Bacterial meningitis 
Purpura fulminans 
Flu-syndrome 
Cerebral malaria 
HIV 
Hepatitis 
Graft versus host 
Allograft rejection 
Systemic vasculitis ? 
Systemic lupus eryth. ? 
Rheumatoid arthritis ? 
Diabetes mellitus (insulin- 
dependent ?? 
? 
? 
Other 
Ischemia/reperfusion injury 
Adult respiratory distress syndrome 
ILZ/LAK therapy 
OKTJ administration 
Chronic lymphocytic leukemia ? 
Hodgkins lymphoma ? 
Atherosclerosis ? 
Cachexia ?? 
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culation. Small doses of TNF can be injected into 
healthy animals without causing much harm, unless 
another stimulus is also added, such as a low concentra- 
tion of LPS which in itself has no effect [72,73]. Jt is im- 
portant to stress that upon infection, either parasitic, 
bacterial or viral, or upon inflammation, not only syn- 
thesis of endogenous TNF is induced, but a whole, in- 
terconnected gang of cytokines is released. The mortali- 
ty due to endotoxic shock can be reduced not only by 
anti-TNF antibodies, but also by an IL1 receptor an- 
tagonist 1741 or by antibodies against IL6 [75]. Also, 
PAF antagonists come to the rescue [SS]. 
The pre-eminent symptom of cachexia or wasting is 
the loss of muscle protein and a negative nitrogen 
balance. This cannot be reproduced by administration 
of TNF to animals using various treatment protocols 
[76]. When TNF is injected daily into mice, there is an 
anorexic effect; the animals stop eating and drinking, 
and there is an arrest of bowel movement [77,78]. But 
after a couple of days the animals recover both their 
weight and their physical fitness. Cancer patients who 
show severe wasting have no TNF in their serum (this 
could of course be a question of detection level). On the 
other hand, Qliff et al. [79] could induce cachexia in 
mice by implantation of TNF-producing CHO-cells; 
but it should be noted that this experiment concerns 
immune-compromised animals, carrying a large tumor 
load, and that the heterologous cells not only secrete 
TNF, but also a number of other cytokines, such as 
IL6 Indeed, in a syngeneic system, we could not 
observe a cachectic activity associated with a TNF- 
producing tumor as compared to animals in which a 
similar tumor with control cells had been raised [80]. 
Various physiological and biochemical studies, which 
as a whole strongly argue that TNF is not the main 
mediator of cachexia, have been discussed in more 
detail by Grunfeld and Feingold [81]. 
6. TNF AND THE CYTOKINE NETWORK 
IL1 is, like TNF, a product of activated macrophages 
(for example, stimulated with LPS). it is most remark- 
able that IL1 exerts on a wide range of cells the same or 
a similar effect as TNF, although both monokines act 
on different receptors, two receptors for TNF and also 
two different receptors for IL1 [50]. Presumably, at 
least in some cells, one of the secondary mediators can 
be induced by either of the two cytokines. However, 
there are a number of activities which they clearly do 
not share. The pre-eminent example is the anti- 
malignant cell cytotoxicity of TNF, especially in com- 
bination with IFN, and which cannot be obtained by 
IL1 treatment. Also, the rapid activation of neutrophils 
by TNF is not seen with IL1 [49]. On the other hand, 
IL1 is a growth factor for an early precursor cell of 
hematopoiesis and is radio-protective, but TNF is not. 
The prototype assay for IL1 is proliferation of 
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thymocytes in the presence of a mitogen. In this test, 
mTNF is clearly active, but far below the levels ob- 
tainable with ILl. Remarkably, hTNF is inactive and is 
even to some extent inhibitory 682,831. Despite the fact 
that on the vast majority of cells, TNF and IL1 exert the 
same range of activities, with a few exceptions as cited 
above, nevertheless upon a single i.v. bolus injection, 
mTNF is far more lethal as compared to IL1 [84]. 
Clearly, TNF must be doing something in vivo which 
does not happen with ILl. It may be stressed here that 
also hTNF has a fairly low toxicity when injected in 
mice; the LD5o is about 50-fold higher [84,85]. Quite 
remarkably, the injection of non-lethal doses of TNF 
together with a small amount of IL1 proved to be lethal; 
there was a high synergy between these cytokines 
[85,86]. Could it be that mTNF is more toxic than 
hTNF in mice, because only the former induces IL1 and 
this combination then acts synergistically? This is not 
so, as no protection against mTNF toxicity could be ob- 
tained by preatreatment with an ILI antagonist [87]. 
Also tumor-bearing animals, which are much more 
susceptible to TNF treatment as compared to controls, 
could not be protected from TNF toxicity by treatment 
with the IL1 antagonist. 
It has long been known that mice treated with galac- 
tosamine become highly sensitive to LPS, and this is 
also true regarding the susceptibility to TNF [88]. The 
LDso for mTNF decreases almost 20-fold and under 
these conditions there is no longer a difference between 
mTNF and hTNF. Galactosamine is a quite specific 
hepatotoxin; it converts all the UTP and in this way 
blocks the metabolism in the hepatocytes. The effect is 
readily reversible with uridine. Clearly, the fact that a 
well-functioning liver is so important for protection 
against TNF toxicity means that either this organ pro- 
duces a protective substance or else is involved in detox- 
ification of a product made as a result of TNF action. 
Remarkably, pretreatment of animals with small doses 
of ILl, optimally at about - 12 h, significantly protects 
against a subsequent TNF challenge, and this protec- 
tion is liver-mediated [89,90]. Possibly, a protective 
substance is induced by IL1 and needs some time to ac- 
cumulate. 
The adrenal glands are another organ which is essen- 
tial for protection against TNF toxicity. Indeed, here, 
upon induction, glucocorticoids are made which on the 
one hand interfere with endogenous TNF synthesis, and 
on the other hand protect cells, including tumor cells, 
from the various actions of TNF. The protective role of 
the glucocorticoids can be demonstrated by adrenalec- 
tomy [91] or by treatment with the glucocorticoid an- 
tagonist RU486 [92]. This drug renders TNF much 
more toxic, but the target where the protective effect of 
the glucocorticoids normally occurs, is not known. It 
may also be mentioned here that TNF causes abortion 
in pregnant mice [93]. Possibly, this may be related to 
the fact that normal embryonic cells are killed by the 
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combination of TNF and IFN-7 [94]. Therefore, it is own unpublished results), precisely the receptor which 
occurs on activated T-cells, as well as on cell types of 
the myeloid lineage. Taking into account the species- 
specific toxicity of TNF in the mouse, these results 
strongly suggest that there is an important contribution 
from TNF-R75-carrying cells (lymphocytes, macro- 
phages, NK-cells, etc,) to the lethal effects. 
conceivable that the abortiogenic effect of RU486 is 
also related to sensitization towards endogenous TNF, 
in addition to its action as a sex steroid hormone an- 
tagonist . 
Both TNF and IL1 are potent inducers of lL6. A 
variety of cells are able to produce lL6: macrophages, 
lymphocytes, endothelial cells, fibroblasts, etc. An in- 
fection or an inflammation may be locally restricted, 
but the IL6 which is produced, circulates through the 
body and sets in motion a variety of reactions. It 
cooperates with colony-stimulating factors in the bone 
marrow, it acts on T- and B-lymphocytes, it causes dif- 
ferentiation of myeloid cells, it acts on the hypotha- 
lamus and causes fever, it stimulates irerve cells, etc. 
But presumably the most important action of IL6 is as 
an inducer of acute phase proteins. The activation of 
some of these genes may require, in addition, gluco- 
corticoids and/or IL1 (reviewed in 195-971). One might 
believe that these activities are beneficial, for example 
some acute phase proteins are anti-proteases, which can 
neutralize the excessive proteolytic activity generated at 
the infection/inflammation site, and the ACTH- 
mediated induction of glucocorticoids protects cells 
from the action of TNF, as mentioned above. 
Of course TNF not only induces new antigens on ef- 
fector cells, but it also stimulates the release of 
cytokines, such as lL6, ILl, GM-CSF, and a variety of 
others. Of special importance among the latter may be 
the IL&type cytokines, which cause migration of 
neutrophils and other white-blood cells to the site of in- 
flammation or to the tumor (reviewed in [103]). 
7. TNF A§ AN ANTITIJMOR AGENT 
Very high levels of IL6 are induced by the action of 
LPS. The peak value is obtained after about 3 h, but by 
6 h the level is back to normal [98]. Also after injection 
of IL1 or hTNF in mice, a peak level of IL6 was obtain- 
ed at about 3 11, which then decreased to background. 
Howevet*, when mTNF was injected which, as mention- 
ed above, finally leads to death, then the IL6 level did 
not decrease, but stayed high, even after 8 h [98,99], We 
found two other conditions where lethality was cor- 
related with a continuous high level of IL6 at late times, 
namely when there was a synergistic toxicity by combin- 
ing hTNF either with IL1 or with RU486 [92]. These 
results could in fact mean that (too much) IL6 is 
deleterious for the organism, a conclusion which is con- 
firmed by the results of Starnes et al. [7.5], who, as men- 
tioned above, could protect mice from TNF-induced 
lethality by administration of antibodies to lL6. 
The assay system which gave TNF its name, is the 
rapid necrosis observed in transplantable, methylcho- 
lanthrene-induced sarcomas in mice [2]. These tumors, 
however, are atypical and hardly a model for cancer in 
man. The Meth-A sarcoma is immunogenic and the 
system is so sensitive that not only hemorrhagic 
necrosis, but also complete elimination of the tumor 
can be obtained with a single injection of a low, non- 
toxic concentration of TNF. It was originally a surprise, 
however, to find that Meth-A sarcoma cells in tissue 
culture were completely resistant to the action of TNF. 
Hence the effect in vivo is entirely host-mediated. The 
endothelium plays a key role in exerting these effects. 
Newly vascularized tumors, about 9 days after the 
original tumor cell inoculation, respond very well, while 
there is no effect at all on the same cells when these were 
injected into the peritoneum. The antitumor effect can 
also be interfered with by administration of an- 
ticoagulants. Moreover, the immune system is impor- 
tant, as tumor necrosis cannot be obtained in syngenic 
nude mice. T-helper cells play an essential role in the 
elimination of the tumor and cured mice become resis- 
tant to a challenge with the same type of tumor cells 
[104]. 
We have rc:ported that mTNF is much more toxic for In our animal model experiments we have chosen a 
mice as compared to hTNF [50,84,85,99], although system which is closer to the course of events in human 
when cytotoxicity is measured in tissue culture, both cancer, namely B16BL6 melanoma tumor in syngenic 
species are almost equivalent [loo]. However, there are C57BL6 mice. This is a fairly aggressive tumor which 
cell systems where a marked difference is observed be- has low immunogenicity. The B16BL6 cells in tissue 
tween mTNF and hTNF. We found that the induction culture are not sensitive to TNF as such, either human 
of cytotoxicity and IL2 receptor expression in a or murine, but become highly sensitive in the presence 
rat/mouse T-cell hybrid could be obtained not only of murine IFN-7 [lQO]. A series of experiments were 
with ILl, but also with mTNF, but not with hTNF carried out in which the in vivo action of mTNF was 
[loll. Later on, as referred to above, other species- compared with hTNF, given either paralesionally (p.l.), 
specific effects on TNF were reported [82,83], such as which means injected in the proximity of the tumor, or 
the proliferation of thymocytes in the presence of a intraperitoneally (i.p.) [105]. These were also the first 
mitogen or the proliferation of some T-cell lines [102]. studies in which the synergy between TNF and IFN was 
We have also mentioned c?%ve that mTNF, but not tested in vivo. A major result was that, using the ap- 
hTNF, interacts with the murine TNF-R75 ([34]; our propriate protocol, elimination of the tumor and com- 
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plete curing could be obtained. But surprisingly, there 
was a very major difference between hTNF and mTNF 
(at that time it was believed that the two TNFs had no 
species specificity); hTNF could only cure when the 
treatment was combined with IFN administration, 
while mTNF was effective as such. We would now inter- 
pret these data as indicating that the action of mTNF 
was mainly host-mediated, while that of hTNF (which 
acts only on TNF-R55, present, amongst others, on 
tumor cells) was to a large extent directly on the tumor 
cells when these were sensitized by IFN. The aggressive, 
but effective protocol used was, however, toxic. More 
than two-thirds of the animals died. Surprisingly, this 
was also true for animals treated with hTNF alone, 
which otherwise is fairly non-toxic; this and several 
later studies revealed that tumor-bearing animals are 
much more sensitive to TNF than controls, and this 
constitutes another major hurdle which has to be over- 
come in order to develop TNF into a useful anti-cancer 
agent. The combimnion of IFN plus TNF as compared 
to the latter alone does not seem to very significantly in- 
crease the toxicity. The main message for the future 
then, was that there T,vas a need to increase the 
therapeutic index, either by decreasing the toxicity or by 
increasing the effectiveness. 
agent alone had no or low activity, and this occurred 
without loss of animals [I12]. 
New approaches can also be developed to reduce the 
toxicity of TNF. We have seen above that a con- 
siderable reduction of toxicity can be achieved by a 
pretreatment with ILl, presumably by activation of a 
protective liver function [89,90]. The toxic effects seen 
after injection of TNF are at least partially due to 
release of prostaglandins, and this can be prevented by 
cycle-oxygenase inhibitors, such as indomethacin [ 1131. 
Although this gives good protection in a single-injection 
experiment, it is, however, counter-productive when the 
treatment has to be repeated for longer times on con- 
secutive days (our unpublished experiments). 
Many more studies regarding Tl’-+lF as an anti-cancer 
agent in animal tumor model systems have been 
reported (reviewed in [55,106]). It should be noted that 
in many animal studies hTNF has been used as this was 
available due to the efforts of a number of biotech- 
nology companies which have developed and produced 
high-grade hTNF for clinical trials. But there are two 
deficiencies which should be highlighted. hTNF in mice 
does not interact with the mTNF-R75, such that an im- 
portant compartment regarding both indirect host ef- 
fects as well as toxicity is not switched on. Furthermore, 
as in tumor studies, repeated treatments have to be 
given, an immune response in the mice against the 
hTNF starts to obscure the picture after a few days. 
It has long been known that when experimental 
animals are treated for a number of days with a low 
concentration of endotoxin, they become refractory to 
a much higher, normally lethal dose of LPS. A simiIar 
induction of tolerance (caIled tolerization or tachyphy- 
laxis) can be obtained by injecting small doses of TNF 
for 5-6 days. Tolerance is induced against certain ef- 
fects of TNF, most importantly the lethality, but not 
against some others. The key question is, how would 
the anti-tumor activity be affected? Fraker et al. [114] 
reported that TNF-tolerized mice carrying an MCA sar- 
coma also had become refractory to a TNF antitumor 
treatment. On the other hand, we found with mice car- 
rying a B16BL6 melanoma, that induction of tolerance 
allowed us to apply an effective treatment with mTNF 
plus mIFN-y [78]. Using p.1. administration, a high 
cure rate was obtained with minimal lethality. The dif- 
fei-ence in response between the two studies is pre- 
sumably again that in the former mainly host-mediated 
processes were involved, while in the latter the protocol 
was aimed at the direct anti-malignant cell activity. The 
studies on induction of TNF tolerance are promising. 
But before they can be transposed to the clinic, much 
more should be known about the underlying 
mechanisms at the cellular and the molecular level. 
As regards the direct action in vivo, the efficacy of A step closer to human cancer is the study of human 
TNF can be enhanced not only by IFN, but also by tumor xenografts in nude mice. As this is human 
some chemotherapeutic drugs [107,108], and especially material, usually these studies are carried out with 
the combination with topoisomerase inhibitors may be hTNF. It should be kept in mind therefore that, because 
promising [109,1 IO]. It should also not be overlooked hTNF does not interact with the mTNF-R75 and 
that the cytotoxic activity of TNF on malignant cells is because nude mice lack TNF-R75-carrying T- 
considerably increased at higher temperatures (the heal- lymphocytes, these model systems do not cover a major 
ing effect of fever?), suggesting that the combination of part of the host-mediated processes. Also, we have seen 
TNF therapy with thermotherapy makes sense [Ill]. above that after a successful treatment immunity 
We have found that the cytotoxic activity of TNF on a develops, and this is not possible in a nude mouse. For 
number of celi lines is dramatically increased in the the same reason, also the toxicity may be much reduced. 
presence of lithium ions [ 1121. The biochemical reason Subcutaneously xenografted tumors derived from 
for this effect is not yet clear. As Li” has low toxicity (it human breast or bowel carcinoma showed a good 
has been used for many years to treat manic depression) response, often complete regression, by intratumoral 
and also does not appreciably increase the toxicity of (i.t.) treatment with TNF [115]. Intraperitoneal (i.p.) 
TNF, it may offer interesting possibilities for therapy. treatment was only marginally effective with some 
With some tumors at least, the treatment with the com- tumors, but the combination with IFN again gave a 
bination TNF plus Li’ was highly effective, while either considerable improvement. Ovarian carcinoma 
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development is rather restricted in the peritoneum, and 
the same is true after xenografting in nude mice. Hence 
i.p. injection allows a fairly local treatment. All four 
human ovarian carcinoma xenografts responded, but in 
quite different ways 11161. One was sensitive to TNF 
alone, another to IFN-7 alone, but still another one was 
uniquely sensitive to a combination of TNF plus 1FN-y 
[116]. It should be noted that in view of the high species 
specificity of IFN-y, this was clearly a direct effect on 
the malignant cells. Further studies with this tumor 
model, however, also revealed a potential complication. 
In the mice treated with TNF, the tumor cells adhered 
to the peritoneal surface, and there was even evidence 
of micro-metastases [ 117,118]. Possibly, one should 
combine the TNF treatment with inhibitors of neo- 
angiogenesis [ 1191. With subcutaneous tumors, 
however, we found that endogenous expression of TNF 
reduced the spreading of tumor cells and seemed to in- 
duce a host-mediated encapsulation of the tumors [SO]. 
The first studies regarding the use of hTNF for treat- 
ment of cancer patients started already in 1985. A con- 
siderable number of clinical trials have now been 
reported (reviewed in [120-1221). In most of these, TNF 
was administered i-v., either as a bolus injection or by 
continuous infusion. The maximum tolerated dose was 
often in the range of 200pg/m2, and it is fair to say that 
no significant anti-tumor responses were noted with 
these systemic treatments. Of course, considering the 
animal tumor model results, one would not have ex- 
pected positive results at these moderate concentration 
levels. The dose-limiting toxicity was often hypoten- 
sion, and occasionally hepatoxicity. There is evidence 
that the former may be due to induction of endothe- 
lium-derived relaxing factor (EDRF), which means NO; 
in animals, this hypotension can be alleviated by adju- 
vant treatment with inhibitors of NO-synthesis [123]. 
Also the hepatoxis effects may be remediable by ap- 
propriate adjuvant therapy. 
studies carried out so far, the response rate is good to 
excellent [I 221. Another route of administration, 
although not so widely applicable, but which certainly 
merits more study, is by way of the lymphatic system 
[ 106]. 
A few clinical studies have so far been reported in- 
volving the combination of TNF plus PFN-7. The max- 
imum tolerated dose of TNF is about 3-fold lower in the 
combination, and again the limiting toxicity is hypoten- 
sion. Also in these combination studies no significant 
anti-tumor activity was observed. 
In view of the results in animal model systems, one 
shouid use on the one hand a more aggressive therapy 
(combinations with IFN, with chemotherapeutic drugs, 
with lithium, with thermotherapy), but at the same time 
reduce the toxicity (appropriate adjuvant treatment, 
tolerization, etc.). But considering the potential lethali- 
ty of TNF, one can only proceed with utmost caution. 
On the other hand, the animal model systems (and the 
earlier results of W. Coley) also showed that a loco- 
regional treatment has a higher chance of success. Of 
course, for the majority of cancer cases, local treatment 
is not an option. But there are alsa many cancer indica- 
tions where local treatment can be used, and in the 
8. TNF: BIOCHEMICAL MECHANISM OF 
ACTION 
The variety of effects exerted by TNF on different 
cell types, and especially the cytotoxic action on many 
malignant cells (mostly in synergy with IFN) as com- 
pared to normal, diploid cells, are intriguing enigmas 
which can only be satisfactorily explained when the 
(presumably multiple) signalling pathways of TNF 
become known in molecular terms. So far, some pieces 
of the puzzle have been put into place, but these are pat- 
ches of knowledge which still cannot be linked up to one 
another. One can distinguish events directly connected 
with the TNF receptor action, early secondary reac- 
tions, and then the two major cellular responses, on the 
one hand, the nucleus-independent cytotoxicity, and on 
the other hand selective transcriptional activation. 
We have seen above that TNF interacts with its recep- 
tor and causes clustering (at Ieast in the case of TNF- 
R55>, the complex becomes internalized and finally is 
degraded in the lysosomes [35]. There is no evidence for 
recycling of the receptor; in the absence of protein syn- 
thesis the receptor does not reappear on the surface 
[ 1241. The receptor is metabolically labile, with a half- 
life of 30 min [ 1251 to 2 h [124]. The cellular response 
correlates with the number of TNF/TNF-R complexes 
internalized, but the number of receptors on the cell 
surface is usually not rate-limiting [ 1241. The TNF 
receptor can be down-modulated by activation of pro- 
tein kinase C, for example with phorbol ester; it is not 
known whether the receptor itself or an accessory pro- 
tein becomes phosphorylated. On the other hand, at 
least in some cell types, protein kinase A up-regulates 
the receptor [126]. Internalization of the complexes is 
presumably required for signalling as chloroquine pro- 
tects cells against cytotoxicity [SS]. We have seen above 
that triggering the receptor can also be obtained by 
cross-linking by means of monoclonal antibodies. This 
has only been shown for the TNF-RSS, but as the latter 
is present on tumor cells and can mediate both cytotoxic 
responses as well as nuclear activation, most of what is 
reported in this section refers in fact to TNF- 
R55-mediated events. It is not yet clear what 
physiological effects the TNF-R75 might have [127]. 
Activation of neutrophils [47,49] and phosphoryla- 
tion of a 27 kDa protein [128] are events which occur 
within 5 min after TNF addition, an! they are protein 
synthesis-independent. The latter phosphorylation is 
not observed in all cells, and might be a side 
phenomenon. As the cytotoxic action is inhibited by a 
pertussis toxin treatment, there might be a G-protein in- 
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volved in the signal transduction [43,129]. But this has known to induce protectina oroteins (see below), in- 
duces manganese s;peroxidedismutase (MnSQD): This 
is a mitochondrial enzyme which deactivates the 
superoxide. Overexpression of MnSOD conferred 
resistance to TNF, while a decrease of enzyme (by 
means of antisense RNA) enhanced the sensitivity. It is 
also of considerable interest that cancer cells are often 
deficient in MnSQD [ 1361. Of course, this enzyme is not 
the only determinant for (inducible) TNF resistance, 
but at least in some cell lines it is a key factor. The 
hypothesis then is that TNF-induced events subvert part 
of the normal electron flow in the mitochondria, and 
redirect it to form oxygen radicals. Recently, direct 
evidence for such disturbances in the electron transfer 
pathway has been obtained [137,138]. As a result of 
these reactive oxygen species, oxidation of lipids and of 
proteins occurs, followed by their degradation; also the 
fragmentation of DNA would be an expected conse- 
quence. 
not yet been directly verified. 
Sensitive cells treated with TNF release arachidonic 
acid into the medium, and this is already significant 
from 1 h onwards [14,43,44,130]. When the cells con- 
tain the appropriate enzymes, this arachidonic acid may 
be converted to prostaglandins [45] and other 
eicosanoids. As arachidonic acid is mainly present in 
the t-position of phospholipids, this TNF-induced 
release suggests the activation of a phopholipase AZ. 
Studies with various inhibitors, such as quinacrine and 
steroids, also point in the same direction [43,129]. 
However, none of these are highly specific and further- 
more the steroids act by indirect mechanisms (but we 
found no evidence for a lipocortin involvement [131]). 
It has been reported that treatment of chondrocytes 
with IL1 actually releases phospholipase A2 into the 
medium, and the same is true for TNF treatment [132]. 
It seems very likely that the activation of a phospho- 
lipase is an essential step in the cytotoxicity: it occurs 
only in TNP-sensitive cells, inhibitors of phospholipase 
activity also protect the cells from the cytotoxic action, 
and vice versa activators, such as Li+ ions, enhance the 
arachidonic acid release as well as the cytotoxicity [44]. 
There is no reason to believe that arachidonic acid or its 
metabolites play a role in killing the cells, but rather it 
is the activation of a phospholipase itself which is essen- 
tial. It may be that at least in some cells phospholipase 
C also becomes activated, but this is presumably not an 
essential step. There is no evidence for a crucial role of 
intracellular calcium influx. Some genes which are ac- 
:ivated by TNF can also become activated by phorbol 
ester (through activation of the transcription factor 
NFxB, see below); but cells treated for a long time with 
phorbol ester such that the protein kinase C is inactive, 
still respond to TNF both with respect to gene activa- 
tion [133], as well as with respect to cytotoxicity (our 
unpublished results). The link between the activation of 
a phospholipase and the next step, which is the actual 
generation of lethal products, is completely unknown. 
Matthews [134] was the first to report that sensitive 
cells treated with TNF show abnormalities in their 
mitochondria; they looked swollen and had fewer 
cristae. On the other hand, we have proposed that reac- 
tive oxygen generated in the target cells is the basis for 
lethal events and leads, amongst others, to lipoxygena- 
tion and to DNA breakdown [14]. That reactive oxygen 
species are involved is further shown by the decreased 
TNF cytotoxicity in anaerobiosis [130]. There was even 
direct evidence for lipid peroxidation, as Matthews et 
al. [ 1301 document the formation of malonyldialdehyde 
(this was only detectable some 20 h after the start of the 
TNF treatment, but this may be due to the low sensitivi- 
ty o’f the detection method). That superoxide generated 
in the mitochondria is a key step in the cytotoxic action 
of TNF is also strongly confirmed by the results of 
Wong et al. [135]. They found that TNF, which is 
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TNF induces the transcription and activation of a 
number of genes in a variety of cell types [55]. Which 
genes become induced depends of course on the par- 
ticular combination of positively and negatively acting 
transcription factors present in that particular cell. The 
prominently induced genes can be revealed by com- 
parative two-dimensional gel electrophoresis /139]. 
Quite often, the set largely overlaps with those induci- 
ble by IL1 [50,140]. But this is not always the case. The 
same protein may be uniquely inducible in one cell type 
by TNF and in another cell type by IL1 [140]. It has 
long been thought that the explanation why cells 
resistant to TNF become sensitive when TNP is com- 
bined with actinom.ycin, is that TNF itself induces pro- 
tective proteins [54]. One of these protective proteins, 
at least in some cells, seems to be MnSOD, as men- 
tioned above. It may be that the dramatic sensitization 
of many cell types by IFN is due to interference by the 
latter cytokine with the induction of protective proteins 
by TNF. One of the better studied proteins induced in 
many cell types by TNF is IL6. There is no correlation 
between sensitivity of the cell to the cytotoxic action of 
TNF and the inducibility of the IL6 gene; the IL6 gene 
can readily be induced not only in normal diploid 
fibroblasts, but also in TNF-resistant tumor cell lines, 
such as MG63 [141]. On the other hand, the IL6 gene 
cannot be induced in the very sensitive WEHI or in 
the human transformed cell lines BT20 or MCF7. But it 
can be induced in the prototype sensitive cell line L929 
[140-1421. TNF induces a rapid, but transient induction 
of c-fos and c-jun, and a more lasting activation of 
NFxB [ 143- 1451. It is of interest that the c-fos and c-jun 
genes may be induced by different signalling pathways 
[144]. There are responsive elements both for the c- 
fos/c-jun complex as well as for the NKKB complex and 
the cyclic AMP-dependent transcription factor in the 
promoter of the IL6 gene [146]. Both TNF and LT ac- 
tivate NFxB within minutes after binding to the recep- 
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tor I145,147,148]; furthermore, triggering either the 
TNF-855 or the TNF-R75 leads to NFxB activation (as 
mentioned above, the biological effects which result 
from TNF-R75 activation, are so far unknown). One 
way to activate NFKB is by stimulation of protein 
kinase C, which presumably phosphorylates the binding 
protein IxB, and in this way releases the ~65 NFKB 
subunit (Fig. 1). The TNF-mediated activation of 
NFxB, however, is protein kinase C-independent [149], 
Several groups have shown by promoter manipulation 
that the induction by TNF of the MI-IC class I genes and 
of the IL6 gene does indeed involve the NFKB respon- 
sive element [148,150-1521. I-Iowever, although NFxB 
activation may be necessary, it might not be the major 
limiting nuclear transcription factor; in L929 cells, we 
found a surprising correlation between cytoplasmically 
determined cytotoxicity and nucleus-dependent IL6 
gene activation, suggesting that both signalling 
pathways have many steps in common ([142]; our un- 
published results). 
Some of the different reaction pathways discussed in 
this section are illustrated in Fig. 1. 
Fig. 1. Model for the mechanism of action of TNF. The trimeric TNF (or LT) interacts with its receptor (TNF-RSS) and by clustering causes inter- 
nalization. The receptor itself is negatively regulated by protein kinase C and positively by protein kinase A. Internalized, clustered TNY receptor 
complexes transmit one or more signals. There is activation of a phospholipase (PL), presumably AZ, and this step may be mediated by a G-protein 
(G). As a result of the phospholipase action, arachidonic acid (AA) is released (which in some cells is converted to prostaglandins, prostacyclins, 
etc.), A signal is transmitted to the mitochondria (M), where the electron transport system is subverted and radicals start to form. These reactive 
oxygen species may eventually kill the cell (oxidation of enzymes, lipids, and degradation of DNA). Another signal, very rapid, leads to activation 
of the transcription factor NFxB (it is not known whether also in this case phosphorylation of the negative regulatory element IKB is involved). 
Transcriptional activation of a number of genes in the nucleus (N) depends on active, nuclear NFxB, but perhaps also on signals from the nudeus- 
independent cytotoxic pathway. Amongst the induced proteins are protective factors which either prevent the formation of toxic products, or else 
detoxify these (e.g. mitochondrial MnSOD). Other activated genes include cell surface antigens (e.g. MHC class I) and secreted proteins (e.g. lL6). 
Not all reactions shown here occur necessarily in the same cell type. Several observations are not yet included in the model, such as the strong 
synergistic action of Li+ and the essential role of a serine-type protease (protection against the cytotoxic effect by serine protease inhibitors [153]). 
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Granger, G.A. and Williams, T.W. (1968) Nature 218, 12.53. 9. CONCEUSION 
There is presumably no other cytokine which has 
such a range of activities on so many cell types as TNF. 
Most probably, its evoiutionary raison d’etre is a 
defense against viral, bacterial and parasitic infections. 
However, due to inappropriate expression, either in 
amount or in time or in localization, it may have very 
detrimental effects on the host. It is becoming very clear 
that TNF plays a key role, most often that of a viIlain, 
in a variety of infectious and inflammatory autoim- 
mune diseases. Due to the complexity of interconnected 
cytokine networks, it is not always easy to distinguish 
which is the main perpetrator and which effects are due 
to the accomplices - it is a story of Dr. Jekyll and Mr. 
Hyde. Clearly, an antagonist of TNF, such as for exam- 
ple soluble TNF receptor, might have many clinically 
valuable applications. 
One should also not underestimate the positive 
potential. Amongst all the cytokines or low-molecular 
weight drugs, there is none which even vaguely 
resembles the selective toxic effect of the combination 
TNF plus IFN on a variety of malignant cells, while 
leaving most normal cells unharmed. At the very least, 
a biochemical understanding of the underlying pheno- 
mena may give us valuable insights as to the difference 
between malignant and normal cell metabolism and/or 
growth control. TNF, in synergy with other drugs, has 
already proven to hold a real potential in locoregional 
cancer therapy. This, I would predict, is only the begin- 
ning as studies involving animal tumor systems have 
provided many indications for improved therapy. In the 
end, we may come to a scientific rationale for effective 
cancer therapy starting from observations made two- 
hundred years ago. 
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